Journal article

An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma

Anna Piggin, H Miles Prince

EXPERT REVIEW OF HEMATOLOGY | TAYLOR & FRANCIS LTD | Published : 2021

Abstract

INTRODUCTION: Despite therapeutic advances, myeloma remains an essentially incurable disease, with a median survival of approximately 8 - 10 years. Most patients will develop disease that is refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs), and treatment regimens containing drugs with different mechanisms of action are necessary. Isatuximab is one such novel agent, an anti-CD38 monoclonal antibody (MoAb), and is the second drug in this class after daratumumab. This paper will consider the current role for isatuximab with pomalidomide for the treatment of relapsed/refractory myeloma (RRMM). AREAS COVERED: This review provides an overview of the pharmacological cha..

View full abstract